The Galleri Test: Accuracy, Limitations, and What $849 Actually Gets You

What the Galleri Test Is

The Galleri Test is a multi-cancer early detection (MCED) blood test developed by GRAIL, a subsidiary of Illumina. Unlike traditional cancer screening tests that look for a single cancer type (mammograms for breast cancer, colonoscopies for colorectal cancer, low-dose CT for lung cancer), the Galleri test analyzes a single blood sample for signals associated with more than 50 different cancer types. It is intended for adults aged 50 and older (or those with elevated cancer risk) as a complement to, not a replacement for, standard screening.

The test returns one of two results: "cancer signal detected" or "cancer signal not detected." When a signal is detected, the test also provides a predicted cancer signal origin (CSO), essentially a best guess at which organ or tissue type the cancer is coming from. This tissue-of-origin prediction is designed to help physicians focus their diagnostic workup rather than ordering scans of every organ system.

How It Works: Cell-Free DNA Methylation

When cells die, they release fragments of DNA into the bloodstream. These fragments are called cell-free DNA (cfDNA). Cancer cells shed cfDNA too, and the Galleri test looks for it. But rather than sequencing the DNA for mutations (which many liquid biopsy tests do), Galleri analyzes methylation patterns. Methylation refers to the addition of methyl groups to specific positions on DNA, which controls gene expression. Different tissue types have distinctive methylation signatures, and cancer cells have aberrant methylation patterns that differ from normal tissue.

The test uses targeted bisulfite sequencing to read methylation patterns across more than 100,000 informative genomic regions. A machine learning classifier then evaluates whether the pattern matches a cancer signal and, if so, which tissue type it most likely originated from. This approach has a key advantage over mutation-based methods: methylation patterns are tissue-specific, which enables the tissue-of-origin prediction that mutation-based approaches cannot easily provide (Klein et al., Ann Oncol, 2021; PMID 34176681).

Accuracy by Cancer Stage: The Numbers You Need to See

The most comprehensive accuracy data comes from the third and final substudy of the Circulating Cell-free Genome Atlas (CCGA), a prospective, case-controlled, observational study. This substudy, published by Klein et al. in Annals of Oncology (2021), included 4,077 participants in an independent validation set: 2,823 with cancer and 1,254 without cancer. The results define what the Galleri test can and cannot do.

Specificity (the ability to correctly identify people without cancer as cancer-free) was 99.5% (95% CI: 99.0% to 99.8%). That means for every 1,000 people without cancer who take the test, roughly 5 would receive a false positive "cancer signal detected" result. For a screening test, this is strong. A low false positive rate matters because false alarms trigger anxiety, unnecessary imaging, biopsies, and medical costs.

Sensitivity (the ability to detect cancer when it is present) varied dramatically by stage. Overall sensitivity across all cancer types was 51.5% (95% CI: 49.6% to 53.3%). By individual stage: Stage I sensitivity was 16.8% (14.5% to 19.5%), Stage II was 40.4% (36.8% to 44.1%), Stage III was 77.0% (73.4% to 80.3%), and Stage IV was 90.1% (87.5% to 92.2%). These numbers tell a clear story: the test is much better at detecting advanced cancers than early-stage ones (Klein et al., Ann Oncol, 2021; PMID 34176681).

For the 12 pre-specified cancer types that account for roughly two-thirds of annual cancer deaths in the United States (including lung, colorectal, pancreatic, ovarian, and liver cancers), combined Stage I through III sensitivity was 67.6% (64.4% to 70.6%). For all cancer types combined, Stage I through III sensitivity was 40.7% (38.7% to 42.9%). This distinction matters because many of the cancers Galleri is designed to catch (pancreatic, ovarian, liver) have no recommended screening test at all.

Which Cancers It Can and Can't Detect

The CCGA validation detected cancer signals across more than 50 cancer types. This is the test's most distinctive feature: it covers cancers for which no standard screening exists. Roughly 70% of cancer deaths in the U.S. come from cancer types with no recommended screening test. Cancers like pancreatic, ovarian, liver, stomach, esophageal, and head and neck cancers are often caught late because there is no routine screening pathway. The Galleri test offers at least some chance of earlier detection for these cancers.

However, sensitivity varies considerably by cancer type. In the CCGA validation, cancers that shed more cfDNA (such as hepatobiliary, head and neck, and colorectal cancers) were detected more reliably, while cancers that shed less cfDNA (such as kidney, thyroid, and prostate) had lower detection rates. The test is not a reliable screening tool for cancers that already have effective screening (like breast, cervical, and colorectal cancer), and GRAIL explicitly states the test should not replace those established screening methods.

One notable gap: the test has limited sensitivity for prostate cancer, the most common cancer in men. The CCGA study showed low detection rates for prostate cancer, likely because most prostate cancers are slow-growing and shed minimal cfDNA. Men should not consider the Galleri test a substitute for PSA-based screening discussions with their physician.

Tissue of Origin Prediction

When the Galleri test detects a cancer signal, it predicts where the cancer is coming from. In the CCGA validation, the overall accuracy of cancer signal origin (CSO) prediction among true positives was 88.7% (95% CI: 87.0% to 90.2%). This means that among participants who truly had cancer and received a "signal detected" result, the test correctly identified the tissue of origin roughly 9 out of 10 times (Klein et al., Ann Oncol, 2021; PMID 34176681).

This feature has practical value. Without tissue-of-origin prediction, a positive multi-cancer blood test would leave physicians with a broad, expensive, and stressful diagnostic workup: whole-body PET-CT, endoscopies, organ-specific imaging, and potentially invasive biopsies. By narrowing the likely source to a specific organ system, the CSO prediction can streamline the path from a positive test to a definitive diagnosis. The PATHFINDER study (NCT04241796), a prospective, interventional, multi-center study of approximately 6,200 participants aged 50 and older, was specifically designed to evaluate how efficiently this diagnostic resolution could occur in clinical practice (Nadauld et al., Cancers, 2021; PMID 34298717).

Who Should Consider the Galleri Test

GRAIL recommends the Galleri test for adults aged 50 and older or those with an elevated risk of cancer. The test is ordered through a healthcare provider. It is not a direct-to-consumer product and should not be taken without a physician who can interpret results and manage follow-up. A "signal detected" result does not mean a person has cancer. It means additional diagnostic workup is needed. A "signal not detected" result does not mean a person is cancer-free. The test misses the majority of Stage I cancers.

The strongest case for the Galleri test is in people who: are over 50 with additional cancer risk factors (family history, smoking history, prior cancer history treated more than 3 years ago); are already up to date on standard screening (mammograms, colonoscopies, lung cancer CT if eligible) and want supplemental coverage for the 50+ cancer types that lack screening; and who understand the test's limitations, particularly the low Stage I sensitivity, and will not interpret a negative result as a clean bill of health.

The weakest case is in someone looking for early-stage cancer reassurance. At 16.8% Stage I sensitivity, the test provides limited peace of mind for very early cancers. It is more useful as a net that catches some cancers that would otherwise go completely undetected until symptoms appear, especially cancers with no other screening pathway.

FDA Status and Insurance Coverage

The Galleri test has received FDA Breakthrough Device designation, which accelerates the review process but does not mean the test is FDA-approved or FDA-cleared. As of March 2026, the Galleri test is available as a laboratory-developed test (LDT) through GRAIL's CLIA-certified laboratory. It has not received premarket approval (PMA) from the FDA. This is an important distinction: Breakthrough Device designation signals that the FDA considers the technology promising enough to warrant an expedited pathway, but regulatory approval still requires demonstration of clinical utility, which means showing that the test leads to meaningful improvements in patient outcomes, not just that it can detect cancer signals.

The NHS-Galleri trial (NCT05611632) in England, the first large randomized controlled trial of a multi-cancer early detection test, was designed to provide this kind of evidence. However, early results reported in 2026 indicated the trial did not meet its primary endpoint of reducing the proportion of late-stage cancer diagnoses (Cancer Discov, 2026; PMID 41817436). Researchers have noted that the surrogate endpoint used (stage shift) may not have been the ideal measure, and longer-term mortality data will be needed. This result has added complexity to the FDA review process and the broader question of clinical utility.

Insurance coverage is effectively nonexistent. Medicare does not cover the Galleri test. Most private insurance plans do not cover it. The test costs $849 out of pocket. GRAIL offers payment plans, but this is a significant expense. Without FDA approval and demonstrated clinical utility (ideally mortality reduction data from randomized trials), broad insurance coverage is unlikely in the near term.

Limitations: What the Galleri Test Cannot Do

The most significant limitation is Stage I sensitivity. At 16.8%, the test misses approximately 5 out of 6 Stage I cancers. For people whose primary motivation is catching cancer as early as possible, this is a substantial gap. The test performs best at detecting cancers that are already at Stage III or IV, where prognosis is generally worse and treatment options are more limited. This creates a paradox: the test is best at finding cancers at the stage when finding them matters least for survival.

Other limitations worth understanding: the test does not replace standard cancer screening. A negative Galleri result should not lead anyone to skip their mammogram, colonoscopy, or Pap smear. The test has a false positive rate of roughly 0.5%, which sounds small but at a population level means that approximately 1 in 200 cancer-free people tested would receive a "cancer signal detected" result and undergo unnecessary diagnostic workup. The test also cannot detect all cancer types with equal reliability, and its performance in real-world screening populations (as opposed to case-controlled validation studies) remains an active area of investigation.

Cost is a genuine barrier. At $849 with no insurance coverage, the test is inaccessible for many people. Whether the cost is justified depends on individual circumstances: a person with multiple cancer risk factors, a strong family history, and the financial means to absorb the cost may find value in supplemental multi-cancer screening. Someone with average risk who is already current on standard screening may get less return on that investment. There is no single right answer, and honest discussions with a healthcare provider about individual risk, test limitations, and what a positive or negative result would mean in context are the most productive path forward.